Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Antoinette J, Wozniak"'
Autor:
Robert Hsu, Denaly Chen, Bing Xia, Rebecca Feldman, Wendy Cozen, Luis E. Raez, Hossein Borghaei, Chul Kim, Misako Nagasaka, Hirva Mamdani, Ari M. Vanderwalde, Gilberto Lopes, Mark A. Socinski, Antoinette J. Wozniak, Alexander I. Spira, Stephen V. Liu, Jorge J. Nieva
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe incidence of lung cancer in the US has been decreasing but a bigger decline has been observed in men despite similar declines in tobacco use between men and women. Multiple theories have been proposed, including exposure to exogenous es
Externí odkaz:
https://doaj.org/article/7acf7bf812854a01ad8168ea2aac8e7a
Autor:
Dong-Wan Kim, MD, PhD, Shirish Gadgeel, MD, Scott N. Gettinger, MD, Gregory J. Riely, MD, PhD, Geoffrey R. Oxnard, MD, Tarek Mekhail, MD, Peter Schmid, MD, PhD, Afshin Dowlati, MD, Rebecca S. Heist, MD, MPH, Antoinette J. Wozniak, MD, Jatinder Singh, PhD, Edward Cha, MD, PhD, Jessica Spahn, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100367- (2022)
Introduction: Alectinib is a preferred first-line treatment option for advanced ALK-positive NSCLC. Combination regimens of alectinib with immune checkpoint inhibitors are being evaluated for synergistic effects. Methods: Adults with treatment-naive,
Externí odkaz:
https://doaj.org/article/ef3f254cb8784bd19307c98d578cc81c
Autor:
Edward B. Garon, Alexander I. Spira, Sarah B. Goldberg, Jamie E. Chaft, Vassiliki Papadimitrakopoulou, Tina Cascone, Scott J. Antonia, Julie R. Brahmer, D. Ross Camidge, John D. Powderly, Antoinette J. Wozniak, Enriqueta Felip, Song Wu, Maria L. Ascierto, Nairouz Elgeioushi, Mark M. Awad
Publikováno v:
Journal of Thoracic Oncology.
Autor:
Antoinette J. Wozniak, Bryan Schneider, Gregory P. Kalemkerian, Bobby Daly, Wei Chen, Jaclyn Ventimiglia, Misako Nagasaka, Marjorie G. Zauderer
Publikováno v:
Clinical Lung Cancer.
Autor:
Stephen V. Liu, Edward S. Kim, Antoinette J. Wozniak, Ari M. Vanderwalde, Alexander I. Spira, Jorge J. Nieva, Patrick C. Ma, Hossein Borghaei, Wolfgang M. Korn, Zoran Gatalica, Jeffrey Swensen, Rebecca A. Feldman, Sushma Jonna
Figure S1 from Detection of NRG1 Gene Fusions in Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a6ab4935ceadd83d7f1caa4e4b63979
https://doi.org/10.1158/1078-0432.22474247
https://doi.org/10.1158/1078-0432.22474247
Autor:
Stephen V. Liu, Edward S. Kim, Antoinette J. Wozniak, Ari M. Vanderwalde, Alexander I. Spira, Jorge J. Nieva, Patrick C. Ma, Hossein Borghaei, Wolfgang M. Korn, Zoran Gatalica, Jeffrey Swensen, Rebecca A. Feldman, Sushma Jonna
Table S1. Descriptions of NRG1 Fusions Identified. *Novel fusion. Abbreviations: NSCLC, non-small cell lung cancer; PDAC, pancreatic ductal adenocarcinoma; GBC, gallbladder cancer (cholangiocarcinoma); CRC, colorectal cancer. RCC, renal cell carcinom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2464e513ba897e63d33fb91a8aeb5e2
https://doi.org/10.1158/1078-0432.22474238.v1
https://doi.org/10.1158/1078-0432.22474238.v1
Autor:
Stephen V. Liu, Edward S. Kim, Antoinette J. Wozniak, Ari M. Vanderwalde, Alexander I. Spira, Jorge J. Nieva, Patrick C. Ma, Hossein Borghaei, Wolfgang M. Korn, Zoran Gatalica, Jeffrey Swensen, Rebecca A. Feldman, Sushma Jonna
Purpose:NRG1 gene fusions are rare but potentially actionable oncogenic drivers that are present in some solid tumors. Details regarding the incidence of these gene rearrangements are lacking. Here, we assessed the incidence of NRG1 fusions across mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cf1f7c37c70454c8e2b4a6742b33913
https://doi.org/10.1158/1078-0432.c.6528734.v1
https://doi.org/10.1158/1078-0432.c.6528734.v1
Autor:
Edward S. Kim, Stephen V. Liu, Rebecca Feldman, Matthew J. Oberley, W. Michael Korn, Sachin Gopalkrishna Pai, Hirva Mamdani, Yasmine Baca, Dipesh Uprety, Chukwuemeka Ikpeazu, Vijendra Singh, Ammar Sukari, Chul Kim, Luis E. Raez, Gerold Bepler, Misako Nagasaka, Joanne Xiu, Alexander I. Spira, Hossein Borghaei, Antoinette J. Wozniak
Publikováno v:
Clinical Lung Cancer. 23:52-59
Background HER2 alteration (mutation and/or amplification) is associated with poor survival in NSCLC and can mediate resistance to EGFR tyrosine kinase inhibitors. Methods We retrospectively analyzed de-identified molecular information from 12,946 NS
Autor:
Seongho Kim, Misako Nagasaka, Amanda Fisher, Kimberly Belzer, Frank A. Baciewicz, Ann G. Schwartz, Ammar Sukari, Hirva Mamdani, Antoinette J. Wozniak, Dina Farhat, Courtney French, MaryAnn Milczuk
Publikováno v:
Clinical lung cancer
Targeted surveillance strategies following initial primary lung cancer (IPLC) treatment are currently limited. One hundred twenty patients diagnosed with IPLC who did not develop second primary lung cancer (SPLC) were matched to 121 patients who deve
Autor:
William Jeffery Edenfield, Daniel Da Costa, David Hoffman, Matthew P. Kosloski, Minal A. Barve, Scott A. Laurie, Alexander Starodub, Jonathan W. Goldman, Satwant Lally, Martina M. Koch, Afshin Dowlati, Antoinette J. Wozniak, Jyoti D. Patel, Grace K. Dy, Taofeek K. Owonikoko
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 2, Pp 664-670 (2021)
Clinical and Translational Science
Clinical and Translational Science
Small cell lung cancer (SCLC) is a leading cause of cancer death worldwide, with few treatment options. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate that targets delta-like 3 on SCLC cells to deliver a cytotoxic payload directly to